Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 28, 2014; 20(12): 3356-3363
Published online Mar 28, 2014. doi: 10.3748/wjg.v20.i12.3356
Published online Mar 28, 2014. doi: 10.3748/wjg.v20.i12.3356
Table 2 Disease-free survival and overall survival of patients in Arm A received different chemotherapy regimens (n = 300)
| n | Cycles median (range) | Disease-free survival (mo) (95%CI) | Overall survival (mo) (95%CI) | |
| Monotherapy | 25 | 4 (2-15) | ||
| Doublet | 164 | 6 (1-17) | 38.4 (21.0-80.3) | 63.2 (22.9-103.5)1 |
| Monotherapy switched | 38 | 8 (3-17) | NR1 | NR1 |
| No monotherapy switched | 126 | 6 (1-12) | 25.4 (18.7-32.1) | 44.4 (28.3-60.5) |
| Triplet | 111 | 6 (2-14) | 45.8 (19.2-72.4)1 | 65.2 (43.5-87.0)1 |
| Monotherapy switched | 35 | 9 (5-14) | NR1 | NR1 |
| No monotherapy switched | 76 | 6 (2-11) | 24.9 (9.4-40.4) | 56.2 (42.0-70.4) |
| Doublet and triplet | 275 | 6 (1-17) | 45.8 (23.8-67.8) | 63.8 (41.4-86.2) |
| Monotherapy switched | 73 | 8 (3-17) | NR1 | NR1 |
| No monotherapy switched | 202 | 6 (1-12) | 25.4 (18.3-32.5) | 49.4 (35.7-63.1) |
- Citation: Deng W, Wang QW, Zhang XT, Lu M, Li J, Li Y, Gong JF, Zhou J, Lu ZH, Shen L. Retrospective analysis of adjuvant chemotherapy for curatively resected gastric cancer. World J Gastroenterol 2014; 20(12): 3356-3363
- URL: https://www.wjgnet.com/1007-9327/full/v20/i12/3356.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i12.3356